5-FU based chemotherapy with Bevacizumab in synchronous metastatic colorectal cancer patients with bleeding primary tumor

Date 29 June 2016
Event ESMO World Congress on Gastrointestinal Cancer 2016
Session ESMO World Congress on Gastrointestinal Cancer 2016 - Abstracts book
Presenter B. Gruenberger
Citation Annals of Oncology (2016) 27 (2): 1-85. 10.1093/annonc/mdw199
Authors B. Gruenberger1, P. Starlinger2, E. Messinger3, S. Weibrecht4, P. Jonas Jan5, B. Weitmayr6, T. Gruenberger7
  • 1Bamherzige Brueder Wien, Dept Internal Med, Vienna, Austria, /
  • 2Departement of Surgery, Medical University Vienna, Vienna, Austria, /
  • 3Pharmacy, Hospital St John of God, Vienna, Austria, /
  • 4Internal Medicine, Hospital St John of God, Vienna, Austria, /
  • 5Dep of Surgery, Rudolfstiftung Hospital, Vienna, Austria, /
  • 6Deep of Pathology, Rudolfstiftung Hospital, Vienna, Austria, /
  • 7University of Vienna, Vienna, Austria, /


The benefit of systemic chemotherapy (5-FU based) in combination with Bevacizumab (Bev) in patients (pts) with metastatic colorectal cancer (mCRC) is well proven. Nevertheless, an anti-VEGF therapy for patients with an intact primary is still controversial. As bleeding is a well-known side effect during treatment with an anti-VEGF therapy Bevacizumab is not recommended in patients with active bleeding. Bev was reported to significantly decrease tumor perfusion, vascular volume and microvascular density. The primary aim of this analysis is to evaluate the safety and efficacy of Bev in patients with clinical bleeding colorectal primary.